Cheahmanda
2021-08-13
Ok
Recap: Jaguar Health Q2 Earnings
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":894791130,"tweetId":"894791130","gmtCreate":1628854206420,"gmtModify":1631889058760,"author":{"id":3575348507224102,"idStr":"3575348507224102","authorId":3575348507224102,"authorIdStr":"3575348507224102","name":"Cheahmanda","avatar":"https://static.tigerbbs.com/85933c7123d4b95f87fbba0cd7951e7f","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ok</p></body></html>","htmlText":"<html><head></head><body><p>Ok</p></body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/894791130","repostId":2159829435,"repostType":4,"repost":{"id":"2159829435","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628852688,"share":"https://www.laohu8.com/m/news/2159829435?lang=&edition=full","pubTime":"2021-08-13 19:04","market":"us","language":"en","title":"Recap: Jaguar Health Q2 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2159829435","media":"Benzinga","summary":" \n\nShares of Jaguar Health (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results.\n\nQuarterly Results\n\nEarnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).","content":"<p>Shares of <b>Jaguar Health</b> (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results.</p>\n<h2>Quarterly Results</h2>\n<p>Earnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).</p>\n<p>Revenue of $385,000 declined by 87.84% from the same period last year, which missed the estimate of $7,280,000.</p>\n<h2>Guidance</h2>\n<p>Jaguar Health hasn't issued any earnings guidance for the time being.</p>\n<p>Revenue guidance hasn't been issued by the company for now.</p>\n<h2>Details Of The Call</h2>\n<p>Date: Aug 13, 2021</p>\n<p>Time: 08:00 AM</p>\n<p>ET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1487163&tp_key=b3a06aa039</p>\n<h2>Recent Stock Performance</h2>\n<p>Company's 52-week high was at $4.47</p>\n<p>52-week low: $0.18</p>\n<p>Price action over last quarter: Up 8.87%</p>\n<h2>Company Profile</h2>\n<p>Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Recap: Jaguar Health Q2 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRecap: Jaguar Health Q2 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-13 19:04</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>Jaguar Health</b> (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results.</p>\n<h2>Quarterly Results</h2>\n<p>Earnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).</p>\n<p>Revenue of $385,000 declined by 87.84% from the same period last year, which missed the estimate of $7,280,000.</p>\n<h2>Guidance</h2>\n<p>Jaguar Health hasn't issued any earnings guidance for the time being.</p>\n<p>Revenue guidance hasn't been issued by the company for now.</p>\n<h2>Details Of The Call</h2>\n<p>Date: Aug 13, 2021</p>\n<p>Time: 08:00 AM</p>\n<p>ET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1487163&tp_key=b3a06aa039</p>\n<h2>Recent Stock Performance</h2>\n<p>Company's 52-week high was at $4.47</p>\n<p>52-week low: $0.18</p>\n<p>Price action over last quarter: Up 8.87%</p>\n<h2>Company Profile</h2>\n<p>Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JAGX":"Jaguar Animal Health, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2159829435","content_text":"Shares of Jaguar Health (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results.\nQuarterly Results\nEarnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).\nRevenue of $385,000 declined by 87.84% from the same period last year, which missed the estimate of $7,280,000.\nGuidance\nJaguar Health hasn't issued any earnings guidance for the time being.\nRevenue guidance hasn't been issued by the company for now.\nDetails Of The Call\nDate: Aug 13, 2021\nTime: 08:00 AM\nET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1487163&tp_key=b3a06aa039\nRecent Stock Performance\nCompany's 52-week high was at $4.47\n52-week low: $0.18\nPrice action over last quarter: Up 8.87%\nCompany Profile\nJaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.","news_type":1},"isVote":1,"tweetType":1,"viewCount":132,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/894791130"}
精彩评论